[1]石 慧,赵 琦,杨月月,等.基于中医传承辅助平台总结当代医家治疗食管癌血瘀痰滞证的用药规律[J].医学信息,2022,35(22):49-54.[doi:10.3969/j.issn.1006-1959.2022.22.008]
　SHI Hui,ZHAO Qi,YANG Yue-yue,et al.Summary of Medication Rules of Contemporary Doctors in Treating Esophageal Cancer of Blood Stasis and Phlegm Stagnation Syndrome Based on Traditional Chinese Medicine Inheritance Support System[J].Journal of Medical Information,2022,35(22):49-54.[doi:10.3969/j.issn.1006-1959.2022.22.008]
点击复制

基于中医传承辅助平台总结当代医家治疗食管癌血瘀痰滞证的用药规律()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
35卷
期数:
2022年22期
页码:
49-54
栏目:
医学数据科学
出版日期:
2022-11-15

文章信息/Info

Title:
Summary of Medication Rules of Contemporary Doctors in Treating Esophageal Cancer of Blood Stasis and Phlegm Stagnation Syndrome Based on Traditional Chinese Medicine Inheritance Support System
文章编号:
1006-1959（2022）22-0049-06
作者:
石 慧; 赵 琦; 杨月月; 等
（1.贵州中医药大学研究生院，贵州 贵阳 550000；2.贵州中医药大学第二附属医院消化内科，贵州 贵阳 550000）
Author(s):
SHI Hui; ZHAO Qi; YANG Yue-yue; et al.
(1.Graduate School of Guizhou University of Traditional Chinese Medicine,Guiyang 550000,Guizhou,China;2.Department of Gastroenterology,the Second Affiliated Hospital of Guizhou University of Traditional Chinese Medicine,Guiyang 550000,Guizhou,China)
关键词:
中医传承辅助平台; 食管癌; 血瘀痰滞证; 用药规律
Keywords:
Traditional Chinese medicine inheritance support platform; Esophageal cancer; Blood stasis phlegm syndrome; Medication rule
分类号:
R272.9
DOI:
10.3969/j.issn.1006-1959.2022.22.008
文献标志码:
A
摘要:
目的 收集整理当代医家治疗食管癌血瘀痰滞证的诊疗信息，探索中医治疗食管癌血瘀痰滞证的用药规律，为食管癌的治疗提供依据及临床研发新药提供参考。方法 收集1992年1月-2022年1月中国期刊网全文数据库（CNKI）中有关中医治疗食管癌血瘀痰滞证的相关文献，基于中医传承辅助平台软件建立相应的数据库，通过频次统计、组方规律、新方分析等，探索当代中医治疗食管癌的常用药物、配伍规则、核心药物组合及挖掘中药新方。结果 共纳入53个方剂，得到治疗血瘀痰滞证中药175味，使用频次≥5的药物有59味，其中常用药物排名前5的分别为半夏、白术、茯苓、甘草、威灵仙；用药模式共36条，其中出现最高频次为16，分别为：白术、茯苓、半夏、代赭石；常用药物规则共36条，置信度最高的分别为：白花蛇舌草->半夏；旋覆花->代赭石；核心药物网络展示共21味药，得出11个新方组合。结论 益气健脾、理气化痰、化瘀散结为治疗食管癌血瘀痰滞证的主要方法，这些方法标本兼施，对本病的临床治疗及组方用药具有重要价值。
Abstract:
Objective To collect and sort out the diagnosis and treatment information of contemporary doctors in the treatment of esophageal cancer with blood stasis and phlegm stagnation syndrome, and to explore the medication rules of traditional Chinese medicine in the treatment of esophageal cancer with blood stasis and phlegm stagnation syndrome, so as to provide basis for the treatment of esophageal cancer and provide reference for clinical research and development of new drugs.Methods The relevant literatures on the treatment of esophageal cancer with blood stasis and phlegm stagnation syndrome by traditional Chinese medicine in CNKI from January 1992 to January 2022 were collected, and the corresponding database was established based on the software of traditional Chinese medicine inheritance auxiliary platform. Through frequency statistics, prescription rules, new prescription analysis, etc., the common drugs, compatibility rules, core drug combinations and new prescriptions of traditional Chinese medicine for the treatment of esophageal cancer were explored.Results A total of 53 prescriptions were included, and 175 Chinese medicines for the treatment of blood stasis and phlegm stagnation syndrome were obtained, while 59 medicines were used more than 5 times. Among them, the top 5 commonly used medicines were Pinellia pinellia, Atractylodes atractylodes, Poria cocos, Licorice licorice, and Willebrand. A total of 36 drug patterns were obtained, among which the highest frequency was 16, which were Atractylodes atractylodes, Poria cocos, Pinellia pinellia and substituted ochre. A total of 36 common drug rules were analyzed, and the highest confidence was: Hedyotis alba -> Pinellia pinellia; Napus -> substitute ochre. The core drug network showed a total of 21 drugs and obtained 11 new prescription combinations.Conclusion Nourishing qi to invigorate spleen, regulating qi and resolving phlegm, removing blood stasis and dissipating mass are the main methods for the treatment of esophageal cancer with blood stasis and phlegm stagnation syndrome. These methods are of great value to the clinical treatment and prescription of this disease.

参考文献/References:

[1]国家卫生健康委员会.食管癌诊疗规范(2018年版)[J].中华消化病与影像杂志（电子版）,2019,9(4):158-192.[2]Bray F,Ferlay J,Soerjomataram I,et al.Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA:A Cancer Journal for Clinicians,2018,68(6):394-424.[3]中华医学会消化内镜学分会,中国抗癌协会肿瘤内镜专业委员会.中国早期食管癌筛查及内镜诊治专家共识意见（2014年，北京）[J].胃肠病学,2015,35(4):220-240.[4]郑玉玲,陈玉龙.中医药治疗食管癌研究述评[J].中医肿瘤学杂志,2020,2(3):1-4.[5]吴耀松,金华彬,陈玉龙,等.健脾和胃法对食管癌细胞株 EC9706 移植瘤生长的抑制作用[J].中华中医药学刊,2019,37(8):1836-1839.[6]郑玉玲,宋学坤,王鑫,等.食管癌放疗后中医证候分型的研究[J].食管疾病,2021,3(3):213-217[7]国家药典委员会.中华人民共和国药典：一部[M].北京:中国医药科技出版社,2020:1-6.[8]李路路,张鼎儒,陈剑,郭宇飞,张睿.四君子汤合沙参麦冬汤加减联合放化疗治疗局部晚期食管鳞癌临床观察[J].山西中医,2019,35(6):16-18.[9]李俊儒,朱颖,张宁苏.从八纲辨证探讨食管癌中医证候分布特点[J].中国民间疗法,2021,29(10):8-11.[10]杨欣,李亚辉,潘恩佳,等.基于 PI3K/Akt 信号通路筛选附子-半夏抗肿瘤的活性成分及关键靶点[J].中国实验方剂学杂志,2019,25(10):170-179.[11]Tian H,Liu Z,Pu Y,et al.Immunomodulatory effects exerted by Poria Cocos polysaccharides via TLR4/TRAF6/NF-κB signaling in vitro and in vivo[J].Biomedicine & Pharmacotherapy,2019,112:108709.[12]刘培,孙芮芮,张莉丹,等.基于网络药理学的四君子汤治疗2型糖尿病的作用机制研究[J].中草药,2020,51(6):1548-1558.[13]韩懿存,陈玉龙,范修琦,等.白术多糖通过靶向miR-34a抑制食管癌细胞免疫检查点PD-L1表达的机制研究[J].中国中药杂志,2022,47(6):1658-1665.[14]朱大诚,况东,徐丽婷,等.黄药子药理作用及临床应用[J].中国老年学杂志,2022,42(1):239-243.[15]李萍,周若瑜,阙月月,等.基于网络药理学的威灵仙抗结直肠癌分子机制研究[J].宜春学院学报,2020,42(3):17-23.[16]王伟,丁爽,龚美源,等.冬凌草甲素抗食管鳞癌转录的组学研究[J].郑州大学学报(医学版),2021,56(4):464-470.[17]Han JM,Hong KO,Yang IH,et al.Oridonin induces the apoptosis of mucoepidermoid carcinoma cell lines in a myeloid cell leukemia 1 dependent manner[J].International Journal of Oncology,2020,57(1):377-385.[18]Ding Y,Ding C,Ye N,et al.Discovery and development of natural product oridonin-inspired anticancer agents[J].European Journal of Medicinal Chemistry,2016,122:102-117.[19]王小兰,段鹏飞,杨梦,等.生地黄多糖对环磷酰胺诱导的免疫抑制小鼠的免疫调节作用研究[J].上海中医药大学学报,2021,35(1):55-60.[20]Kwak M,Yu K,Lee PCW,et al.Rehmannia glutinosa polysaccharide functions as a mucosal adjuvant to induce dendritic cell activation in mediastinal lymph node[J].International Journal of Biological Macromolecules,2018,120:1618-1623.

相似文献/References:

[1]汪 兵,杜 铭.食管癌微创手术与机器人手术的研究[J].医学信息,2018,31(06):34.[doi:10.3969/j.issn.1006-1959.2018.06.012]
　WANG Bing,DU Ming.Study on Minimally Invasive Surgery and Robotic Surgery for Esophageal Carcinoma[J].Journal of Medical Information,2018,31(22):34.[doi:10.3969/j.issn.1006-1959.2018.06.012]
[2]许益芬.三维适型放疗与调强放疗在胸中段食管癌根治性放疗中的 剂量学比较[J].医学信息,2018,31(13):73.[doi:10.3969/j.issn.1006-1959.2018.13.021]
　XU Yi-fen.Dosimetric Comparison of Three-dimensional Conformal Radiotherapy and Intensity-Modulated Radiotherapy for Radical Radiotherapy of Middle Thoracic Esophageal Carcinoma[J].Journal of Medical Information,2018,31(22):73.[doi:10.3969/j.issn.1006-1959.2018.13.021]
[3]茹仙古丽·艾尔西丁,木拉提·哈米提,严传波,等.RF和C4.5决策树在食管癌图像分类中的研究[J].医学信息,2018,31(22):51.[doi:10.3969/j.issn.1006-1959.2018.22.015]
　Roxangvl·Arxidin,Murat·Hamit,YAN Chuan-bo,et al.Research on RF and C4.5 Decision Tree in Image Classification of Esophageal Cancer[J].Journal of Medical Information,2018,31(22):51.[doi:10.3969/j.issn.1006-1959.2018.22.015]
[4]刘 慧,付 雅,皈 燕,等.呼吸动度对食管癌靶区影响及呼吸运动管理策略[J].医学信息,2022,35(12):93.[doi:10.3969/j.issn.1006-1959.2022.12.022]
　LIU Hui,FU Ya,GUI Yan,et al.Effect of Respiratory Movement on Esophagus Cancer Target Volume and Respiratory Motility Management Stratege[J].Journal of Medical Information,2022,35(22):93.[doi:10.3969/j.issn.1006-1959.2022.12.022]
[5]万 芳.以贫血为首发症状的消化道恶性肿瘤临床分析[J].医学信息,2018,31(24):175.[doi:10.3969/j.issn.1006-1959.2018.24.054]
　WAN Fang.Clinical Analysis of Digestive Tract Malignancies with Anemia as the First Symptom[J].Journal of Medical Information,2018,31(22):175.[doi:10.3969/j.issn.1006-1959.2018.24.054]
[6]张小艳,赵 红,郑穗生,等.食管癌患者放射性肺损伤预测因素分析及其与 COPD的相关性研究[J].医学信息,2019,32(14):68.[doi:10.3969/j.issn.1006-1959.2019.14.022]
　ZHANG Xiao-yan,ZHAO Hong,ZHENG Sui-sheng,et al.Predictive Factors Analysis of Radiation-Induced Lung Injury in Patients with Esophageal Cancer and Its Correlation with COPD[J].Journal of Medical Information,2019,32(22):68.[doi:10.3969/j.issn.1006-1959.2019.14.022]
[7]赵素素,谭洁琼,党 娟.食管癌术后恢复期补液量与术后恢复的关系[J].医学信息,2021,34(04):88.[doi:10.3969/j.issn.1006-1959.2021.04.023]
　ZHAO Su-su,TAN Jie-qiong,DANG Juan.The Relationship Between the Amount of Fluid Supplementation in the Recovery Period and Postoperative Recovery of Esophageal Cancer[J].Journal of Medical Information,2021,34(22):88.[doi:10.3969/j.issn.1006-1959.2021.04.023]
[8]杨玥欣,汪 志,杨 欣,等.食管癌放疗的剂量学和临床疗效研究[J].医学信息,2020,33(04):72.[doi:10.3969/j.issn.1006-1959.2020.04.022]
　YANG Yue-xin,WANG Zhi,YANG Xin,et al.Dosimetry and Clinical Efficacy of Radiotherapy for Esophageal Cancer[J].Journal of Medical Information,2020,33(22):72.[doi:10.3969/j.issn.1006-1959.2020.04.022]
[9]文 龙,张 彬.食管癌的治疗现状及趋势分析[J].医学信息,2022,35(18):165.[doi:10.3969/j.issn.1006-1959.2022.18.046]
　WEN Long,ZHANG Bin.Treatment Status and Trend Analysis of Esophageal Cancer[J].Journal of Medical Information,2022,35(22):165.[doi:10.3969/j.issn.1006-1959.2022.18.046]
[10]刘安东,刘崇华,王园园.参麦注射液联合放射治疗对中晚期食管癌老年患者的疗效[J].医学信息,2020,33(16):152.[doi:10.3969/j.issn.1006-1959.2020.16.048]
　LIU An-dong,LIU Chong-hua,WANG Yuan-yuan.The Effect of Shenmai Injection Combined with Radiotherapy on Elderly Patients with Advanced Esophageal Cancer[J].Journal of Medical Information,2020,33(22):152.[doi:10.3969/j.issn.1006-1959.2020.16.048]

更新日期/Last Update: 1900-01-01